Boilerplate clauses

Boilerplate clauses

This subtopic focuses on boilerplate clauses in commercial business-to-business agreements. For information on commercial clauses more generally, see: Commercial clauses—overview.

For information on boilerplate in business-to-consumer contracts, see the section on ‘Consumer boilerplate’ below.

For information on boilerplate in public sector contracts, see the section on ‘Public sector boilerplate’ below.

The role of boilerplate

Lawyers work on a huge variety of transactions, but all of them will in some way involve written agreements. All of those agreements should contain some boilerplate clauses.

‘Boilerplate’ is the term used to describe the clauses that are included in an agreement to deal with the mechanics of how it works and those legal points that are relevant to most transactions. For further consideration of the role and importance of boilerplate clauses, see Practice Note: The role of boilerplate.

Boilerplate clauses are generally found at the beginning and the end of an agreement. Such clauses are often thought of as standard, miscellaneous provisions, but this is a very dangerous view to adopt. It is not unusual for a boilerplate clause to be the cause of litigation. Since a boilerplate clause

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

EMA report shows major expansion of real-world evidence framework in 2024-25

The European Medicines Agency (EMA) has published its third annual report on its Real-World Evidence (RWE) framework, covering February 2024 to February 2025. The report details a 47.5% increase in RWE studies to 59 total, with the DARWIN EU network expanding to 30 data partners across 16 countries, covering 180 million patients. The framework achieved a 78% feasibility rate for studies, up from 60% previously, with a median completion time of 4 months. Studies focused on drug utilisation (42%), safety monitoring (24%) and disease epidemiology (24%), supporting regulatory decision-making across multiple EMA committees and stakeholders.

Commission launches strategy to boost life sciences in Europe

The European Commission has launched a Life Science Strategy designed to position Europe as the world’s most attractive region for life sciences by 2030 while addressing systemic issues that have long hindered the region’s competitiveness and limited patient access to cutting-edge treatments. Supported by over €10bn annually, the strategy aims to accelerate innovation, enhance market access, and build public trust across the entire life sciences value chain.

Life Sciences weekly highlights—3 July 2025

This week's edition of Life Sciences weekly highlights includes analysis from partners of Hogan Lovells on the key takeaways from new MDCG 2025-6 guidance on the interplay between the Medical Device Regulation/In Vitro Diagnostic Medical Device Regulation and the EU AI Act. Also included, is news that the MHRA opened applications for an expanded AI Airlock programme following last year’s pilot and published the much-anticipated guidance to support implementation of the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, which come into force on 28 April 2026; the European Commission adopted new rules allowing all medical devices used by professionals to include electronic instructions for use; the DHSC announced the development of an AI system to monitor NHS patient safety in real time; and the European Notified Bodies industry group (TEAM-NB) released an updated version of its position paper on software classification under the IVDR, among other stories.

DHSC and NHS England announce new 'innovator passport' system for healthcare technology

The Department of Health and Social Care (DHSC) and NHS England have announced plans to introduce an 'innovator passport' system over the next two years. The digital system, delivered through the MedTech Compass platform, will enable healthcare technology assessed by one NHS organisation to be implemented across other NHS bodies without requiring repeated compliance assessments. The initiative forms part of the government's 10 Year Health Plan and aims to streamline technology adoption processes across the NHS. The system will operate as a centralised platform for NHS organisations to access information about assessed healthcare technologies and their supporting evidence.